6955 Stock Overview
A development stage company, manufactures medical instruments and solutions for the male infertility market. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Bonraybio Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | NT$141.00 |
52 Week High | NT$162.50 |
52 Week Low | NT$71.04 |
Beta | 0 |
1 Month Change | 0.36% |
3 Month Change | 4.44% |
1 Year Change | 90.09% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 87.67% |
Recent News & Updates
Recent updates
Shareholder Returns
6955 | TW Biotechs | TW Market | |
---|---|---|---|
7D | -0.4% | -3.5% | -1.6% |
1Y | 90.1% | 1.1% | 28.6% |
Return vs Industry: 6955 exceeded the TW Biotechs industry which returned 1.1% over the past year.
Return vs Market: 6955 exceeded the TW Market which returned 28.6% over the past year.
Price Volatility
6955 volatility | |
---|---|
6955 Average Weekly Movement | 3.7% |
Biotechs Industry Average Movement | 4.2% |
Market Average Movement | 4.5% |
10% most volatile stocks in TW Market | 7.9% |
10% least volatile stocks in TW Market | 2.0% |
Stable Share Price: 6955 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6955's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | n/a | n/a | bonraybio.com |
Bonraybio Co., Ltd., a development stage company, manufactures medical instruments and solutions for the male infertility market. The company provides LensHooke X12 PRO semen analysis systems; and LensHooke X1 PRO semen quality analyzers. It also offers consumables, such as CS3 semen test slides; CA0/CA1 sperm separation solutions; and CS1 semen test cassettes.
Bonraybio Co., Ltd. Fundamentals Summary
6955 fundamental statistics | |
---|---|
Market cap | NT$2.77b |
Earnings (TTM) | NT$0 |
Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs 6955 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
6955 income statement (TTM) | |
---|---|
Revenue | NT$0 |
Cost of Revenue | NT$0 |
Gross Profit | NT$0 |
Other Expenses | NT$0 |
Earnings | NT$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did 6955 perform over the long term?
See historical performance and comparison